Whalegun

Insider trades

Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.

Open-market buys
934 trades
$2B in total
Open-market sales
1,045 trades
$2.3B in total
Insiders filing
467 insiders
Last 7 days
Companies with several buyers
27
Last 7 days
Atea Pharmaceuticals AVIR
Trade type
Polly A. MurphyDirector
Atea PharmaceuticalsAVIR
Open-market buyAmendment05/1805/216,100 sh$4.17$25,437+7.1%
Polly A. MurphyDirector
Atea PharmaceuticalsAVIR
Open-market buy25/05/1805/206,100 sh$4.17$25,437+7.1%
Director
Atea PharmaceuticalsAVIR
Open-market buyAmendment25/01/15–25/01/1625/01/1750,000 sh4 trades$3.26avg.$162,900No record
Franklin M. BergerDirector
Atea PharmaceuticalsAVIR
Open-market sale24/12/1024/12/12359,606 sh$2.85$1,024,877.1−44.3%
President, CEO, and Chairman
Atea PharmaceuticalsAVIR
Open-market sale10b5-1 plan24/09/17–24/09/1924/09/1957,969 sh3 trades$4.04avg.$234,238.66−1.0%
Bruce PolskyDirector
Atea PharmaceuticalsAVIR
Open-market sale24/06/2024/06/2117,544 sh$3.49$61,228.56−21.1%
Jean-Pierre SommadossiPresident, CEO, and Chairman
Atea PharmaceuticalsAVIR
Open-market sale10b5-1 plan24/06/0524/06/071,006 sh$4.00$4,024−0.0%
Jean-Pierre SommadossiPresident, CEO, and Chairman
Atea PharmaceuticalsAVIR
Open-market sale10b5-1 plan24/02/0124/02/0256,910 sh$3.85$219,103.5−32.8%
Andrea CorcoranSEE REMARKS
Atea PharmaceuticalsAVIR
Open-market sale24/02/0124/02/0215,843 sh$3.84$60,837.12−2.3%
Wayne FosterEVP, Chief Accounting Officer
Atea PharmaceuticalsAVIR
Open-market sale24/02/0124/02/0212,477 sh$3.84$47,911.68−37.4%
Maria Arantxa HorgaChief Medical Officer
Atea PharmaceuticalsAVIR
Open-market sale24/02/0124/02/0215,870 sh$3.84$60,940.8−38.2%
John VavrickaChief Commercial Officer
Atea PharmaceuticalsAVIR
Open-market sale24/02/0124/02/0211,819 sh$3.84$45,384.96−35.5%
Janet Mj HammondChief Development Officer
Atea PharmaceuticalsAVIR
Open-market sale24/02/0124/02/0214,029 sh$3.84$53,871.36−28.4%